The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Feasibility and preliminary safety and efficacy of first-in-human intraperitoneal delivery of MCY-M11, anti-human-mesothelin CAR mRNA transfected into peripheral blood mononuclear cells, for ovarian cancer and malignant peritoneal mesothelioma.
 
Christina M. Annunziata
Research Funding - MaxCyte (Inst); Medivir (Inst); Precision Biologics (Inst)
Patents, Royalties, Other Intellectual Property - MaxCyte (Inst); Precision Biologics (Inst)
 
Armin Ghobadi
Honoraria - Kite, a Gilead company
Consulting or Advisory Role - Amgen; Celgene; Kite, a Gilead company; WUGEN, Inc.
Speakers' Bureau - Kite, a Gilead company
Research Funding - Amgen; Kite, a Gilead company
 
Eduardo J. Pennella
Employment - MaxCyte
Stock and Other Ownership Interests - MaxCyte
 
Julie Vanas
Employment - Maxcyte; Wellstat Diagnostics
Stock and Other Ownership Interests - • CVS HEALTH CORP COM; Alnylam; Anthem; Humana; Intuitive Surgical; Johnson & Johnson; Quest Diagnostics; Thermo Fisher Scientific; United Health Group
 
Charles Powell
No Relationships to Disclose
 
Mira Pavelova
No Relationships to Disclose
 
Cathy Wagner
No Relationships to Disclose
 
Michael Kuo
No Relationships to Disclose
 
Claudio Dansky Ullmann
No Relationships to Disclose
 
Raffit Hassan
Research Funding - Aduro Biotech (Inst); Bayer (Inst); Morphotek (Inst); TCR2 Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Mesothelin domain-specific monoclonal antibodies and use thereof (Patent number:9803022)
 
Premal H. Thaker
Stock and Other Ownership Interests - Celsion
Consulting or Advisory Role - Abbvie/Stemcentrx; Abbvie/Stemcentrx; Celsion; Clovis Oncology; Dova Pharmaceuticals; Iovance Biotherapeutics; Stryker; Tesaro; Unleash
Speakers' Bureau - AstraZeneca; Merck; Tesaro
Research Funding - Merck (Inst)